GIPL vs ZTS Stock Comparison

Global Innovative Platforms and Zoetis Prices as of Oct 26, 2026 Peers: Industry group
ZTS Zoetis Inc.
$78.21 +10.1% 1M -47.0% 1Y
Market cap
$32.39B
P/E
12.5x
Revenue (TTM)
$9.52B
Div. yield
2.67%
Animal Health Healthcare
5 wins

Head to Head

7 decided of 12

Zoetis leads on 5 of the 12 questions below (Zoetis 5, Global Innovative Platforms 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGIPLZTSLeader
Larger companyMarket capitalisation $24.88M $32.39B ZTS
Cheaper on earningsLower P/E, profitable companies only -36.0x 12.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 13.3x –
Faster revenue growthRevenue growth, trailing twelve months — +1.5% –
More profitableNet margin, trailing twelve months -361.7% 27.5% ZTS
Better return on capitalReturn on invested capital — 23.4% –
Less leveragedLower net debt / EBITDA 0.4x 1.8x GIPL
Higher dividend yieldTrailing dividend yield — 2.67% –
Better 1-year returnPrice return, last 12 months -37.5% -47.0% GIPL
Better 5-year returnAnnualised price return, 5 years -36.9%/yr -18.1%/yr ZTS
Less volatileAnnualised volatility, 1 year 271.4% 40.6% ZTS
Higher overall scoreMean of the five percentile scores vs peers 55/100 72/100 ZTS

Percentile Scorecard

GIPLZTS

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGIPLZTS
Valuation 62 #241 of 625 88 #74 of 625
Growth 27 #442 of 602 52 #292 of 602
Profitability 39 #335 of 551 96 #23 of 551
Financial Health 98 #12 of 656 34 #436 of 656
Shareholder Returns 50 #183 of 365 90 #39 of 365
Overall 55 72
  • GIPL ranked among 672 companies in Pharmaceuticals and Biotechnology
  • ZTS ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGIPLZTSSPY
1 month 0.0%+10.1% -0.2%
3 months 0.0%+0.9% +3.9%
6 months -3.8%-33.0% +8.2%
Year to date +354.5%-37.8% +12.9%
1 year -37.5%-47.0% +12.3%
3 years -52.4%-49.9% +87.4%
3 years, per year -21.9%-20.6% +23.3%
5 years -90.0%-63.2% +67.9%
5 years, per year -36.9%-18.1% +10.9%
10 years -82.9%+60.4% +261.1%
10 years, per year -16.2%+4.8% +13.7%

Risk

MeasureGIPLZTSSPY
Volatility, 1Y 271.4%40.6% 12.7%
Downside volatility, 1Y —49.2% 12.7%
Beta vs S&P 500, 1Y 2.270.52 1.00
Return / volatility, 1Y -0.14-1.16 0.97
Max drawdown, 5Y -98.0%-72.0% -25.4%
From 52-week high -49.5%-47.0% -1.2%
52-week high $0.99$147.53 $779.14
52-week low $0.11$69.12 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGIPLZTS
P/E now vs peer median -36.0xmedian 17.2x 12.5xmedian 17.2x
P/S now vs peer median 132.9xmedian 9.0x 3.4xmedian 9.0x
EV/EBITDA now vs peer median -39.5xmedian 16.3x 9.8xmedian 16.3x
P/FCF now vs peer median -32.5xmedian 18.7x 14.0xmedian 18.7x
P/B now vs peer median 46.8xmedian 2.2x 10.3xmedian 2.2x
PEG now vs peer median -0.57median 0.33 1.33median 0.33

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGIPLZTS
Revenue $187.20K $9.52B
Gross profit – $6.81B
Operating income -$677.04K $3.59B
Net income -$677.04K $2.62B
Free cash flow -$766.04K $2.32B
R&D $377.99K $722.00M
EPS (diluted) $-0.02 $6.26
Cash & equivalents $244.24K $1.48B
Total debt $8.62K $9.05B
Shares (diluted) 44.54M 417.70M
Enterprise value $24.27M $24.24B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGIPLZTS
P/E -36.0x 12.5x
P/FCF -32.5x 14.0x
P/Operating cash flow -35.0x 11.4x
P/S 132.9x 3.4x
P/B 46.8x 10.3x
P/Tangible book 47.1x 14.5x
EV/EBITDA -39.5x 9.8x
EV/EBIT -36.4x 11.1x
EV/Revenue 131.6x 4.2x
EV/FCF -32.2x 17.2x
EV/Operating cash flow -34.7x 14.0x
PEG (3Y EPS CAGR) -0.57 1.33

Growth

14 metrics
MetricGIPLZTS
Revenue growth (1Y) – 1.5%
Revenue CAGR (3Y) – 5.0%
Gross profit growth (1Y) – 1.8%
Gross profit CAGR (3Y) – 5.7%
Operating income growth (1Y) -20.9% -0.1%
Operating income CAGR (3Y) -51.6% 5.2%
Net income growth (1Y) -20.9% 0.6%
Net income CAGR (3Y) -51.6% 5.7%
EPS growth (1Y) -9.8% 7.7%
EPS CAGR (3Y) 63.5% 9.4%
Operating cash flow growth (1Y) 15.8% -4.6%
Operating cash flow CAGR (3Y) -96.8% 12.4%
Free cash flow growth (1Y) 9.2% 2.1%
Free cash flow CAGR (3Y) -101.8% 21.7%

Profitability

14 metrics
MetricGIPLZTS
Gross margin – 71.5%
EBITDA margin -333.4% 42.8%
Operating margin -361.7% 37.7%
Pretax margin -361.7% 34.4%
Net margin -361.7% 27.5%
FCF margin -409.2% 24.3%
Operating cash flow margin -379.8% 29.8%
Return on equity -120.8% 82.0%
Return on assets -119.7% 17.3%
Return on invested capital – 23.4%
Return on capital employed -121.4% 27.5%
Asset turnover 0.3x 0.6x
Cash conversion (OCF / net income) 1.1x 1.1x
Stock comp / revenue – 1.0%

Financial Health

11 metrics
MetricGIPLZTS
Debt / assets 1.0% 60.0%
Debt / equity 0.0x 2.9x
Net debt / EBITDA 0.4x 1.8x
Debt / FCF 0.0x 3.9x
Liabilities / assets 1.4% 79.1%
Equity / assets 98.6% 20.9%
Interest coverage – 15.1x
Current ratio 34.7x 3.1x
Quick ratio 33.2x 1.6x
Cash ratio 31.3x 0.8x
Altman Z-score 1,908 4.75

Shareholder Returns

7 metrics
MetricGIPLZTS
Dividend yield – 2.7%
Net buyback yield -3.2% 11.3%
Shareholder yield -3.2% 13.9%
Payout ratio (earnings) – 34.0%
Payout ratio (FCF) – 38.4%
Dividend growth (1Y) – 6.1%
Dividend CAGR (3Y) – 10.9%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGIPLZTS
Forward P/E – 13.3xFY2026
EPS, next fiscal year – $5.86FY2026
EPS growth, next FY – -8.6%FY2026
EPS growth, the year after – +13.0%
Revenue, next fiscal year – $9.57BFY2026
Revenue growth, next FY – +1.0%FY2026
Revenue growth, the year after – -7.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGIPLZTS
Held by institutions – 94.7%
Institutions holding – 1,417
Change in shares held, QoQ – -2.6%
Institutions buying – 674
Institutions selling – 582
Buyers to sellers – 1.16

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GIPLZTS
GIPL 1.00 0.02
ZTS 0.02 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GIPL and ZTS?

Zoetis (ZTS) is the largest by market capitalisation: Global Innovative Platforms (GIPL) $24.88M, Zoetis (ZTS) $32.39B.

Which company is more profitable?

Zoetis (ZTS) has the highest net margin (Global Innovative Platforms (GIPL) -361.7%, Zoetis (ZTS) 27.5%).

Which stock has performed better?

Over the past year Global Innovative Platforms (GIPL) returned the most: Global Innovative Platforms (GIPL) -37.5%, Zoetis (ZTS) -47.0%. Over five years, Zoetis (ZTS) compounded fastest (Global Innovative Platforms (GIPL) -36.9%/yr, Zoetis (ZTS) -18.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Zoetis (ZTS) 2.67%. Global Innovative Platforms (GIPL) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Zoetis (ZTS) has been the steadiest (Global Innovative Platforms (GIPL) 271.4%, Zoetis (ZTS) 40.6%). Volatility measures how widely the price swings, not the risk of the business.

Do GIPL and ZTS move together?

Their daily returns over the past year have a correlation of 0.02, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, GIPL and ZTS?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Zoetis (ZTS) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.